RxDoctor Payments Data

Shawna Seelbach

Family · Norman, OKNPI 1578069407

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 34 payments — averaging $35.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$502
  • GSK$207
  • AbbVie$127
  • Janssen Scientific Affairs, LLC$124
  • AstraZeneca$112
  • Novartis$69
  • plus $76 from 2 others

What the payments were for

  • Food & beverage$95178%
  • Education$26522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,216 in reported general payments places this provider in the 70th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$355,351
Medicare patients
232
Services billed
19,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab56$753,676
Enbrel SureclickEtanercept29$228,066
RemicadeInfliximab27$129,352
BenlystaBelimumab31$127,205
Cosentyx Sensoready PenSecukinumab12$120,067
RinvoqUpadacitinib14$90,442
SaphneloAnifrolumab-Fnia11$56,747
Teriparatide17$42,437
ActemraTocilizumab15$27,861
Hydroxychloroquine Sulfate477$15,574
TrintellixVortioxetine Hydrobromide11$5,202
Celecoxib109$3,081
Sulfasalazine106$2,645
MethotrexateMethotrexate Sodium185$2,586
Leflunomide76$2,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRemicade$502$129,35227 claims
GSKBenlysta$207$127,20531 claims
AbbVieRinvoq$127$90,44214 claims
AstraZenecaSaphnelo$112$56,74711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,026 family providers in Oklahoma.

Other family in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →